In recent developments, Novo Nordisk has faced significant blows. The stock plunged, losing over 19% in one day due to a disappointing trial result from obesity drug CagriSema. Although Wegovy, another weight-loss solution by the company, saw better than anticipated sales, it wasn't enough to offset the sharp fall. Despite the setback, Intriguingly, the stock made big movements both midday and premarket. There was instance of retail investors flocking towards the stock following the drug setback. In comparison with fellow pharmaceutical giants Eli Lilly and Viking, Novo Nordisk appeared to be at a disadvantage, yet some consider its current low price a rare buying opportunity. The question of whether the stocks may recover to $145 levels is also raised. A contrasting viewpoint arises as the BMO analyst suggests that Novo Nordisk is 'losing its pep' in the GLP-1 race. Given the substantial stock drop, many wonder if it's the right time to buy Novo Nordisk. As a growth stock, it's considered one of the most profitable, yet a warning against weaker Wegovy sales looms.
Novo Nordisk Stocks News Analytics from Wed, 11 Sep 2024 07:00:00 GMT to Sat, 28 Dec 2024 11:05:00 GMT -
Rating -8
- Innovation 4
- Information 10
- Rumor 2
